To Assess the Prevalence, Management Practices, and Clinical Outcomes Associated With Hyperglycem… (NCT07626775) | Clinical Trial Compass
CompletedNot Applicable
To Assess the Prevalence, Management Practices, and Clinical Outcomes Associated With Hyperglycemia Among Hospitalized Patients, With a Particular Focus on the Interplay Between Metabolic Biomarkers, Nutritional Status, and Body Composition
India362 participantsStarted 2023-01-01
Plain-language summary
This was a prospective, observational cross-sectional study conducted at a tertiary care private hospital in India. The study was designed to comprehensively evaluate the prevalence, management strategies, and clinical outcomes of in-hospital hyperglycemia among adult inpatients. The study also explored the associations of metabolic biomarkers-fetuin-A and fibroblast growth factor-21 (FGF-21) as well as sarcopenic obesity and nutritional factors with clinical outcomes, including length of hospital stay (LOS), complications, and mortality. Institutional Ethics Committee approval was obtained prior to study initiation, and written informed consent was secured from all participants
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients aged ≥18 years.
* Patients with known or newly diagnosed type 2 diabetes mellitus (T2DM) or those presenting with hyperglycemia (random blood glucose ≥140 mg/dL) during hospitalization.
* Both medical and surgical inpatients admitted for ≥24 hours
Exclusion Criteria:
* Pregnant or lactating women.
* Patients with type 1 diabetes mellitus or other specific types of diabetes (e.g., pancreatogenic, drug-induced).
* Patients with chronic liver disease unrelated to diabetes or hepatic dysfunction secondary to viral hepatitis, autoimmune hepatitis, or alcohol abuse.
* Critically ill patients requiring palliative care or those with advanced malignancy
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study has already been completed — does that mean the results are available, and if so, what did they find about how common high blood sugar is in hospitalized patients and how it affects outcomes?
2The trial looked at the connection between blood sugar levels, nutritional status, and body composition — given my own situation with diabetes, should I be asking you to assess those factors if I'm ever hospitalized?
3Since this was an observational study measuring what already happens to patients rather than testing a new treatment, does it change any of your current recommendations for how my blood sugar should be managed if I need to go to the hospital?
4The study focused specifically on people with diabetes and high blood sugar in the hospital setting — based on findings like this, are there protocols or best practices you'd want to put in place for me ahead of any planned hospital stay?
5This trial tracked metabolic biomarkers alongside blood sugar control — are there specific lab values or body composition measurements I should be monitoring now to reduce my risk of complications if I'm ever hospitalized?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
To determine the prevalence of hyperglycemia
Timeframe: 10 Days
2
Assess clinical outcomes associated with hyperglycemia